237 related articles for article (PubMed ID: 17009934)
1. Drotrecogin alfa (activated) in the treatment of severe sepsis.
Vincent JL
Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934
[TBL] [Abstract][Full Text] [Related]
2. Drotrecogin alfa: a new approach in the treatment of severe sepsis.
Vincent JL
Expert Opin Biol Ther; 2002 Aug; 2(6):659-64. PubMed ID: 12171509
[TBL] [Abstract][Full Text] [Related]
3. Drotrecogin alfa (activated) in the treatment of severe sepsis.
Vincent JL
Curr Drug Saf; 2007 Sep; 2(3):227-31. PubMed ID: 18690972
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
[TBL] [Abstract][Full Text] [Related]
5. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D
Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
[TBL] [Abstract][Full Text] [Related]
6. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
7. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C; Matthews SJ
Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
[TBL] [Abstract][Full Text] [Related]
8. Drotrecogin alpha (activated): the treatment for severe sepsis?
Vincent JL
Expert Opin Biol Ther; 2007 Nov; 7(11):1763-77. PubMed ID: 17961098
[TBL] [Abstract][Full Text] [Related]
9. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST; Isakow W; Shannon W; Kollef MH
Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
[TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
11. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
[TBL] [Abstract][Full Text] [Related]
12. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).
Rudis MI; Fish DN
Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225
[TBL] [Abstract][Full Text] [Related]
14. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
Bernard GR
Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981
[TBL] [Abstract][Full Text] [Related]
15. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*.
Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD
Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090
[TBL] [Abstract][Full Text] [Related]
16. Role of activated protein C in the pathophysiology of severe sepsis.
Dettenmeier P; Swindell B; Stroud M; Arkins N; Howard A
Am J Crit Care; 2003 Nov; 12(6):518-24; quiz 525-6. PubMed ID: 14619357
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
[TBL] [Abstract][Full Text] [Related]
18. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
Yan SB; Nelson DR
Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
[TBL] [Abstract][Full Text] [Related]
19. Drotrecogin alfa (activated).
Lyseng-Williamson KA; Perry CM
Drugs; 2002; 62(4):617-30; discussion 631-2. PubMed ID: 11893230
[TBL] [Abstract][Full Text] [Related]
20. Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.
McCoy C
Expert Opin Drug Saf; 2004 Nov; 3(6):625-37. PubMed ID: 15500421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
